|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.03.26 - 05:25
|
Hua Medicine on Earnings, Business Expansion Plans (Bloomberg)
|
|
|
Chinese biotech firm Hua Medicine sees robust growth in 2026 after reporting a 93% jump in full-year revenue. Speaking exclusively to Bloomberg's "The China Show," Chief Strategy Officer George Lin discusses the outlook for the company's flagship drug dorzagliatin and plans to expand to additional markets. (Source: Bloomberg)...
|
|
|
30.03.26 - 05:19
|
Innovent Biologics Bullish on China Obesity Drug Outlook (Bloomberg)
|
|
|
Innovent Biologics has reported its first profit even as competition from weight-loss generics looms. Speaking exclusively to Bloomberg's "The China Show," CFO Rachel You says China's obesity drug market has massive potential and could mirror current penetration rates in the US. (Source: Bloomberg)...
|
|
|
30.03.26 - 04:48
|
Chinese company to use AI-powered chromosome testing to boost profits and fast track IVF (SCMP)
|
|
|
Biotech firm Hangzhou Diagens Biotechnology is banking on AI-powered chromosome testing to drive profit growth following its Hong Kong listing, as China's falling fertility rate spurs demand for assisted reproduction.
“In China, many young people do not want to marry or have children, and by the time they decide to start a family, they need medical help to do so,” Diagens' founder and executive director, Song Ning, said.
“We are meeting an increasing number of couples every year who struggle to......
|
|
|
|
|
30.03.26 - 02:30
|
Huawei sees 60% surge in Taiwan earphone sales, targets wearables expansion (Digitimes)
|
|
|
Huawei Technologies unveiled its 2026 wearable product lineup at a launch event in Taiwan on the March 27. Yong Hai, general manager of Xunwei Technology, the exclusive distributor for Huawei in Taiwan, highlighted that the company achieved a remarkable 60% year-over-year increase in earphone sales revenue in 2025 despite lacking a smartphone product line in Taiwan....
|
|
|
|
|
|
|
|
|
29.03.26 - 23:30
|
Foreign brokerages cut India Inc′s earnings, index targets (Times of India)
|
|
|
Foreign broking major Goldman Sachs has cut the Nifty target to 25,900 points from 29,300 points earlier while Citigroup has revised down their target for the index to 27,000 points from 28,500 points earlier. On its part, HSBC said that historical trend shows that a 20% rise in oil price could drag down earnings of India Inc by 1.3 percentage points. Since the war started crude oil prices are up about 50-55%....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
